Above all, we make a difference.
Home > Breast Cancer Information > Diagnosis > Diagnosis References

Diagnosis References

  1. American Cancer Society. Breast biopsy. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/breast-biopsy.html, 2024.
  2. American Cancer Society. Risks of cancer surgery. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/surgery/risks-of-cancer-surgery.html, 2019.
  3. Dana-Farber Cancer Institute. Top myths about breast cancer. https://blog.dana-farber.org/insight/2015/10/ten-myths-about-breast-cancer-infographic/, 2021.
  4. Mayo Clinic. Cancer treatment myths: any truth to these common beliefs? https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer/art-20046762, 2024.
  5. Sung JS and Comstock CE. Chapter 15: Image-guided biopsy of nonpalpable breast lesions, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  6. Brancato B, Crocetti E, Bianchi S, et al. Accuracy of needle biopsy of breast lesions visible on ultrasound: audit of fine needle versus core needle biopsy in 3233 consecutive samplings with ascertained outcomes. Breast. 21(4):449-54, 2012.
  7. Rouse HC, Ussher S, Kavanagh AM, Cawson JN. Examining the sensitivity of ultrasound-guided large core biopsy for invasive breast carcinoma in a population screening programme. J Med Imaging Radiat Oncol. 57(4):435-43, 2013.
  8. Wang M, He X, Chang Y, Sun G, Thabane L. A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions: A systematic review and meta-analysis. Breast. 31:157-166, 2017.
  9. Ly A, Ono JC, Hughes KS, Pitman MB, Balassanian R. Fine-needle aspiration biopsy of palpable breast masses: patterns of clinical use and patient experience. J Natl Compr Canc Netw. 14(5):527-36, 2016.
  10. Hoda RS, Brachtel EF. International Academy of Cytology Yokohama system for reporting breast fine-needle aspiration biopsy cytopathology: a review of predictive values and risks of malignancy. Acta Cytol. 63(4):292-301, 2019.
  11. Bleicher RJ. Chapter 4: Management of the palpable breast mass, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  12. Moffat FL. Chapter 28: Clinical and pathologic prognostic and predictive factors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  13. Chung AP, Giuliano AE. Chapter 37: Sentinel lymph node biopsy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast cancer treatment, Version 5.2024. http://www.nccn.org, 2024.
  15. Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 364(5):412-21, 2011.
  16. Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 306(4):385-93, 2011.
  17. Joe BN. Clinical features, diagnosis, and staging of newly diagnosed breast cancer. In: UpToDate. Burstein H, Vora SR (eds.). Waltham, MA: UpToDate, 2024.
  18. Bleiweiss IJ. Pathology of breast cancer. In: UpToDate. Chagpar AB, Vora SR (eds.). Waltham, MA: UpToDate, 2024.
  19. Dillon D, Guidi AJ, Schnitt SJ. Chapter 25: Pathology of Invasive Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  20. National Cancer Institute. Inflammatory breast cancer. http://www.cancer.gov/types/breast/ibc-fact-sheet, 2016.
  21. Taghian A and Merajver SD. Inflammatory breast cancer: Clinical features and treatment. In: UpToDate (Hayes DF, Pierce LJ, Chagpar AB, Vora SR, eds.). Waltham, MA: UpToDate, 2024.
  22. Sabel MS, Weaver DL. Paget disease of the breast (PDB). In: UpToDate (Chagpar AB, Hayes DF, Pierce LJ, Chen W, eds.). Waltham, MA: UpToDate, 2024.
  23. Terando AM, Agnese DM, Holmes DR. Treatment and prognosis of rare breast cancers. Ann Surg Oncol. 22(10):3225-9, 2015.
  24. Lee H, Jung SY, Ro JY, et al. Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol. 65(5):441-6, 2012.
  25. Leyrer CM, Berriochoa CA, Agrawal S, et al. Predictive factors on outcomes in metaplastic breast cancer. Breast Cancer Res Treat. 165(3):499-504, 2017.
  26. Ong CT, Campbell BM, Thomas SM, et al. Metaplastic breast cancer treatment and outcomes in 2500 patients: a retrospective analysis of a national oncology database. Ann Surg Oncol. 25(8):2249-2260, 2018.
  27. Oesterreich S, Nasrazadani A, Zou J, et al. Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer. J Natl Cancer Inst. 114(11):1511-1522, 2022.
  28. Schulze AK, Hoskin TL, Moldoveanu D, Sturz JL, Boughey JC. Tumor characteristics of bilateral breast cancer compared with unilateral breast cancer. Ann Surg Oncol. 31(2):947-956, 2024.
  29. Sakai T, Ozkurt E, DeSantis S, et al. National trends of synchronous bilateral breast cancer incidence in the United States. Breast Cancer Res Treat. 78(1):161-167, 2019.
  30. Öztekin S, Hooning MJ, van Deurzen CHM, et al. The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study. Cancer. 130(6):927-935, 2024.
  31. Weiser R, Polychronopoulou E, Hatch SS, et al. Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: A National Cancer Database analysis. Cancer. 128(9):1738-1747, 2022.
  32. Surveillance Research Program, National Cancer Institute. SEERExplorer. Breast cancer-SEER 5-year relative survival rates, 2014-2020, by subtype, female, all races/ethnicities, all ages, all stages. Accessed on July 8, 2024. https://seer.cancer.gov/explorer/, 2024.
  33. Chamalidou C, Fohlin H, Albertsson P, et al. for the Swedish western and south-eastern breast cancer groups. Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. Breast. 59:294-300, 2021.
  34. Yoon, TI, Jeong J, Lee S, et al. Survival outcomes in premenopausal patients with invasive lobular carcinoma. JAMA Netw Open. 6(11):e2342270, 2023.
  35. Anders CK, Carey LA. ER/PR negative, HER2-negative (triple negative) breast cancer. In: UpToDate. Hayes DF, Burstein HJ, Vora SR (eds.). Waltham, MA: UpToDate, 2024.
  36. Limaiem F, Khan M, Lotfollahzadeh S. Lobular breast carcinoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554578/, 2023.
  37. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment—breast, ovarian and pancreatic cancer. Version 2.2024. http://www.nccn.org, 2024.
  38. Ryan CE, Fasaye GA, Gallanis AF, et al. Germline CDH1 variants and lifetime cancer risk. JAMA. 332(9):722-729, 2024.
  39. Hu C, Nart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 384(5):440-451, 2021.
  40. Petridis C, Arora I, Shah V, et al. Frequency of pathogenic germline variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in sporadic lobular breast cancer. Cancer Epidemiol Biomarkers Prev. 28(7):1162-1168, 2019.
  41. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332: 1589-93, 1995.
  42. Beral V for the Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 362:419-27, 2003.
  43. Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 128(1):144-56, 2011.
  44. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 394(10204):1159-1168, 2019.
  45. Wang SM, Pfeiffer RM, Gierach GL, Falk RT. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort. Breast Cancer Res. 22(1):129, 2020.
  46. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 324(4):369-380, 2020.
  47. Li C, Daling JR, Haugen KL, Tang, MTC, Porter PL, Malone KE. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age. Breast Cancer Res Treat. 145(2):481-9, 2014.
  48. American Cancer Society. Hormone therapy for breast cancer. https://www.cancer.org/cancer/types/breast-cancer/treatment/hormone-therapy-for-breast-cancer.html, 2024.
  49. Schandiz H, Park D, Kaiser YL, et al. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact. Breast Cancer Res Treat. 201(2):329-338, 2023.
  50. Carey LA, Cheang MCU, Perou CM. Chapter 29: Genomics, Prognosis, and Therapeutic Interventions, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
  51. Foukakis T, Bergh J. Prognostic and predictive factors in early, non-metastatic breast cancer. In: UpToDate. Burstein HJ, Vora SR (eds.). Waltham, MA: UpToDate, 2024.
  52. Metzger-Filho O, Sun Z, Viale G, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 31(25):3083-90, 2013.
  53. McGuire A, Lowery AJ, Kell MR, Kerin MJ, Sweeney KJ. Locoregional recurrence following breast cancer surgery in the trastuzumab era: a systematic review by subtype. Ann Surg Oncol. 24(11):3124-3132, 2017.
  54. Partridge AH, Hughes ME, Warner ET, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 34(27):3308-14, 2016.
  55. Scott LC, Mobley LR, Kuo TM, Il’yasova D. Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014. Cancer. 125(19):3412-3417, 2019.
  56. Troester MA, Sun X, Allott EH, et al. Racial differences in PAM50 subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. 110(2):176-182, 2018.
  57. Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 384(5):440-451, 2021.
  58. Mavaddat N, Dorling L, Carvalho S, et al. for the Breast Cancer Association Consortium. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. 8(3):e216744, 2022.
  59. Surveillance Research Program, National Cancer Institute. SEERExplorer. HR-/HER2- Breast cancer (female only). SEER 5-year age-adjusted incidence rates, 2017-2021. Female by race/ethnicity, all ages, all stages. Accessed on May 6, 2024. https://seer.cancer.gov/explorer/, 2024.
  60. Martínez ME, Gomez SL, Tao L, et al. Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. Breast Cancer Res Treat. 166(1):185-193, 2017.
  61. Rey-Vargas L, Sanabria-Salas MC, Fejerman L, Serrano-Gómez SJ. Risk factors for triple-negative breast cancer among Latina women. Cancer Epidemiol Biomarkers Prev. 28(11):1771-1783, 2019.
  62. Surveillance Research Program, National Cancer Institute. SEERExplorer. HR-/HER2- Breast cancer (female only). Recent trends in SEER relative survival rates, 2010-2021. Female, all stages by race/ethnicity, 5-year relative survival, all ages. Accessed on May 6, 2024. https://seer.cancer.gov/explorer/, 2024.
  63. Surveillance Research Program, National Cancer Institute. SEERExplorer. Breast cancer- HR+/HER2- breast cancer (female only). Recent trends in SEER age-adjusted incidence rates, 2010-2021. Observed SEER incidence rate, female by race/ethnicity, all ages, all stages. Accessed on October 14, 2024. https://seer.cancer.gov/explorer/, 2024.
  64. Chollet-Hinton L, Olshan AF, Nichols HB, et al. Biology and etiology of young-onset breast cancers among premenopausal African American women: results from the AMBER Consortium. Cancer Epidemiol Biomarkers Prev. 26(12):1722-1729, 2017.
  65. Sarink D, White KK, Loo LWM, et al. Racial/ethnic differences in postmenopausal breast cancer risk by hormone receptor status: The multiethnic cohort study. Int J Cancer. 150(2):221-231, 2022.
  66. Walsh SM, Zabor EC, Stempel M, Morrow M, Gemignani ML. Does race predict survival for women with invasive breast cancer? Cancer. 125(18):3139-3146, 2019.
  67. American Cancer Society. Breast Cancer Facts and Figures 2024-2025. Atlanta, GA: American Cancer Society, 2024.
  68. National Cancer Institute. BRCA1 and BRCA2: cancer risks and management (PDQ®) – health professional version. https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq, 2024.
  69. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 103(3):250-63, 2011.
  70. Warner ET, Tamimi RM, Boggs DA, et al. Estrogen receptor positive tumors: do reproductive factors explain differences in incidence between black and white women? Cancer Causes Control. 24(4):731-9, 2013.
  71. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 137(1):307-14, 2013.
  72. Palmer JR, Viscidi E, Troester MA, et al. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst. 106(10), 2014.
  73. Chen L, Li CI, Tang MT, et al. Reproductive factors and risk of luminal, HER2-overexpressing, and triple-negative breast cancer among multiethnic women. Cancer Epidemiol Biomarkers Prev. 25(9):1297-304, 2016.
  74. Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL for the Breast Cancer Surveillance Consortium. Risk factors that increase risk of estrogen receptor-positive and -negative breast cancer. J Natl Cancer Inst. 109(5): djw276, 2016.
  75. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat. 137(2):579-87, 2013.
  76. Schoemaker MJ, Nichols HB, Wright LB, et al. for the Premenopausal Breast Cancer Collaborative Group. Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol. 4(11):e181771, 2018.
  77. Chan DSM, Abar L, Cariolou M, et al. World Cancer Research Fund International: Continuous Update Project-systematic literature review and meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk. Cancer Causes Control. 30(11):1183-1200, 2019.
  78. Warner ET, Tamimi RM, Hughes ME, et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 33(20):2254-61, 2015.
  79. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 313(2):165-73, 2015.
  80. American Cancer Society. Cancer Facts & Figures for African Americans: 2022-2024. Atlanta, GA: American Cancer Society, 2022.
  81. Cho B, Han Y, Lian M, et al. Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative breast cancer. JAMA Oncol. 7(7):1016-1023, 2021.
  82. Houssami N, Turner R, Macaskill P, et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol. 32(5):392-401, 2014.
  83. Sardanelli F, Trimboli RM, Houssami N, et al. Magnetic resonance imaging before breast cancer surgery: results of an observational multicenter international prospective analysis (MIPA). Eur Radiol. 32(3):1611-1623, 2022.
  84. Feigelson HS, James TA, Single RM, et al. Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg. 216(5):966-75, 2013.
  85. Arnaout A, Catley C, Booth CM, et al. Use of preoperative magnetic resonance imaging for breast cancer: a Canadian population-based study. JAMA Oncol. 1(9):1238-50, 2015.
  86. Vapiwala N, Hwang WT, Kushner CJ, Schnall MD, Freedman GM, Solin LJ. No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy. Cancer. 123(8):1324-1332, 2017.
  87. Houssami N, Turner RM, Morrow M. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. Breast Cancer Res Treat. 165(2):273-283, 2017.
  88. Wang SY, Long JB, Killelea BK, et al. Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat. 172(2):453-461, 2018.
  89. Han Y, Jung JG, Kim JI, et al. The percentage of unnecessary mastectomy due to false size prediction using preoperative ultrasonography and MRI in breast cancer patients who underwent neoadjuvant chemotherapy: a prospective cohort study. Int J Surg. 109(12):3993-3999, 2023.
  90. Fairbairn K, Cervantes A, Rayhrer R, Steen S. Trends in contralateral prophylactic mastectomy. Aesthetic Plast Surg. 44(2):323-329, 2020.
  91. McDonald ES, Scheel JR, Lewin AA, et al. for the Expert Panel on Breast Imaging. ACR Appropriateness Criteria® imaging of invasive breast cancer. J Am Coll Radiol. 21(6S):S168-S202, 2024.
  92. Bidard FC, Michiels S, Riethdorf S, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 110(6):560-567, 2018.
  93. Sparano J, O’Neill A, Alpaugh K, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4(12):1700-1706, 2018.
  94. Trapp E, Janni W, Schindlbeck C, et al. for the SUCCESS Study Group. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst. 111(4):380-387, 2019.
  95. Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 5(10):1473-1478, 2019.
  96. Radovich M, Jiang G, Hancock BA, et al. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial. JAMA Oncol. 6(9):1410-1415, 2020.
  97. Cristofanelli M, Budd GT, Ellis MJ, Stopeck AS, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351(8):781-91, 2004.
  98. Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 15(4):406-14, 2014.
  99. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 368(13):1199-209, 2013.
  100. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 32(31):3483-9, 2014.
  101. Henry NL, Somerfield MR, Dayao Z, et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. J Clin Oncol. 40(27):3205-3221, 2022.
  102. Chia S. Prognostic and predictive factors in metastatic breast cancer, in UpToDate (Burstein HJ, Vora SR, eds.). Waltham, MA: UpToDate, 2024.
  103. Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 67(4):290-303, 2017.
  104. Abele N, Tiemann K, Krech T, et al. Noninferiority of Artificial Intelligence-assisted analysis of Ki-67 and estrogen/progesterone receptor in breast cancer routine diagnostics. Mod Pathol. 36(3):100033, 2023.
  105. Retamero JA, Gulturk E, Bozkurt A, et al. Artificial Intelligence helps pathologists increase diagnostic accuracy and efficiency in the detection of breast cancer lymph node metastases. 48(7):846-854, 2024.
  106. Anampa JD, Lin S, Obeng-Gyasi S, Xue X. Treatment and survival differences between patients with invasive lobular carcinoma versus invasive ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev. 34(1):125-132, 2025.
  107. National Cancer Institute. Cancer stat facts: invasive lobular carcinoma. https://seer.cancer.gov/statfacts/html/ilc.html, 2024.

Updated 03/06/25

This content is regularly reviewed by an expert panel including researchers, practicing clinicians and patient advocates.

TOOLS & RESOURCES

PDF

Fact Sheet

Support After a Breast Cancer Diagnosis

PDF

Fact Sheet

What is Breast Cancer?